SUTRO BIOPHARMA, INC.
310 Utah Avenue,
Suite 150
South San Francisco, CA 94080
October 9, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Office of Life Sciences | |
Re: | Sutro Biopharma, Inc. Registration Statement on FormS-3 Filed October 4, 2019 FileNo. 333-234101 |
Requested Date: October 11, 2019
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statementon Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely,
Sutro Biopharma, Inc. | ||
By: | /s/ Edward C. Albini | |
Edward C. Albini | ||
Chief Financial Officer |
cc: | William J. Newell, Chief Executive Officer Sutro Biopharma, Inc.
Amanda Rose, Esq. Ryan Mitteness, Esq. Fenwick & West LLP |